The drug is now in Phase 2 clinical trials in patients with Alzheimer’s and Fragile X syndrome
A new drug discovered through a research collaboration between the University at Buffalo and Tetra Therapeutics may protect against memory loss, nerve damage and other symptoms of Alzheimer’s disease.
Preclinical research found that the drug — called BPN14770 — deters the effects of amyloid beta, a hallmark protein of Alzheimer’s that is toxic to nerve cells.
Recent studies find Alzheimer’s may develop without dementia in nearly 25% of healthy 80-year-old patients, suggesting the body may turn to compensatory mechanisms to maintain the nervous system.
BPN14770, under development by Tetra Therapeutics, could help activate these mechanisms that support nerve health and prevent dementia, even with the progression of Alzheimer’s.
Its benefits could also translate to Fragile X syndrome, developmental disabilities and schizophrenia, researchers say.
“Such observations imply that Alzheimer’s pathology can be tolerated by the brain to some extent due to compensatory mechanisms operating at the cellular and synaptic levels,” said Ying Xu, MD, PhD, co-lead investigator and research associate professor in the UB School of Pharmacy and Pharmaceutical Sciences.
“Our new research suggests that BPN14770 may be capable of activating multiple biological mechanisms that protect the brain from memory deficits, neuronal damage and biochemical impairments.”
The study, published on Sept. 5 in The Journal of Pharmacology and Experimental Therapeutics, was also led by James M. O’Donnell, PhD, dean and professor of the UB School of Pharmacy and Pharmaceutical Sciences. Mark E. Gurney, PhD, chairman and chief executive officer of Tetra Therapeutics, based in Grand Rapids, Michigan, collaborated on the research.
Guarding memory against toxic proteins
The research, conducted in mice, discovered that BPN14770 inhibits the activity of phosphodiesterase?4D (PDE4D), an enzyme that plays a key role in memory formation, learning, neuroinflammation and traumatic brain injury.
PDE4D lowers cyclic adenosine monophosphate (cAMP) — a messenger molecule that signals physiological changes such as cell division, change, migration and death — in the body, leading to physical alterations in the brain.
cAMP has numerous beneficial functions, including improved memory. By inhibiting PDE4D, BPN14770 increases cAMP signaling in the brain, which ultimately protects against the toxic effects of amyloid beta.
“The role of PDE4D in modulating brain pathways involved in memory formation and cognition, and the ability of our PDE4D inhibitor to selectively enhance this process, has been well studied,” said Gurney. “We are very excited by our colleagues’ findings, which now suggest a second protective mechanism of action for BPN14770 against the progressive neurological damage associated with Alzheimer’s disease.”
“Developing effective drugs for memory deficits associated with Alzheimer’s disease has been challenging,” said O’Donnell. “BPN14770 works by a novel mechanism to increase cyclic AMP signaling in the brain, which has been shown to improve memory. The collaborative project has led to clinical trials that will begin to test its effectiveness.”
Tetra Therapeutics is conducting Phase 2 clinical trials of BPN14770 in patients with early Alzheimer’s and adults with Fragile X syndrome, a genetic disorder that causes intellectual and developmental disabilities.
Results of previous Phase 1 studies in healthy elderly volunteers suggest the drug benefits working, or immediate, memory. Animal studies found that BPN14770 has the potential to promote the maturation of connections between neurons, which are impaired in patients with Fragile X syndrome, as well as protect these connections, which are lost in patients with Alzheimer’s.
“There has been enormous interest in our ongoing Phase 2 trial of BPN14770 in 255 patients with early Alzheimer’s, and we are hopeful this study will show an impact of PDE4D modulation in this disease. Topline results are expected mid-2020,” said Gurney.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Understanding Alzheimer's Disease Mechanismson October 15, 2019 at 1:29 am
Factors that increase the chance of developing Alzheimer’s disease later in life include diabetes, age and having two copies of the gene for apolipoprotein E 4 (APOE ε4). A research group led by ...
- Conference offers help and support so families don’t have to face Alzheimer’s aloneon October 14, 2019 at 8:45 pm
The challenges of dealing with Alzheimer’s disease can be overwhelming, and no one should have to face it alone. That’s the philosophy behind the “Educating America Tour,” which the Alzheimer’s ...
- Faith Episcopal Church to Host Alzheimer's Workshop on Oct. 25on October 14, 2019 at 8:42 pm
Join us at Faith Episcopal, Laguna Niguel for an informational evening on Friday, October 25, 2019 at 6:00 p.m. as Alzheimer's Orange County will share the facts about Alzheimer's. Presented by Donna ...
- Hundreds gather at Nymeo Field for Walk To End Alzheimer’son October 14, 2019 at 5:05 pm
If there’s someone who knows something about the effect Alzheimer’s disease can have on a family, it’s Julie Peatt Cassaday. Her father died as a result of having it after a taxing battle and while ...
- Port St. Lucie Walk to End Alzheimer’s raises nearly $100,000 to fight diseaseon October 14, 2019 at 2:12 pm
Port St. Lucie Walk to End Alzheimer’s raises nearly $100,000 to fight disease “Alzheimer’s is destroying our families, our finances and our future,” said Audra Afflitto, chief executive director for ...
- Alzheimer's Association raises nearly $100,000 at Walk to End Alzheimer's in Port St. Lucieon October 14, 2019 at 2:00 pm
Nearly 1,000 residents from across the Treasure Coast joined the Walk to End Alzheimer’s on Sept. 28 at the Port St. Lucie Civic Center. Participants raised more than $95,708 for the Alzheimer's ...
- This Philly College Student Is Running 100 Consecutive 5Ks for Alzheimer’s Diseaseon October 14, 2019 at 10:03 am
Today marks his official halfway point, his 50th run. Widrig’s endeavor is both altruistic and deeply personal, as he is running to raise awareness and research funds for finding a cure to Alzheimer’s ...
- Sleep issues tied to Alzheimer’son October 14, 2019 at 7:49 am
Sleep disturbances may cause a decline in neurocognitive functioning, which could precede Alzheimer's disease or other dementias among Hispanics, according to a study. (Dreamstime) Hispanics who have ...
- Changes associated with Alzheimer's disease detectable in blood sampleson October 14, 2019 at 6:28 am
Researchers have discovered changes in blood samples associated with Alzheimer's disease. A new international study examined disease-discordant twin pairs: one sibling who suffered from Alzheimer ...
- Can Any Good Come From Alzheimer’s?on October 14, 2019 at 5:03 am
The truth: Alzheimer’s and other dementia diseases are always a burden on loved ones. The lesser-known truth: Dealing with the diseases can provide positive impacts of a temporary or even lasting ...
via Bing News